BriaCell Therapeutics Corp. (BCTX) Key Statistics & Financial Ratios

BriaCell Therapeutics Corp. (BCTX) — Price $3.56 — Healthcare — Biotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for BriaCell Therapeutics Corp. (BCTX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer.

Stock Data

Price$3.56
Market Cap$31M
Enterprise Value$24.1M
Beta1.63
ExchangeNASDAQ
CountryCA

Valuation Multiples

P/E Ratio-0.29
Price / Book1.07
P/S0.00
EV/EBITDA-0.76
EV/Sales0.00
EV/FCF-0.78
P/FCF-1.00
Earnings Yield-118.85%
FCF Yield-100.00%
Dividend Yield0.00%

Profitability

Gross Margin0.00%
EBIT Margin0.00%
EBITDA Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Return on Equity-147.92%
Return on Assets-113.23%
Return on Invested Capital-136.31%
Return on Capital Employed-136.31%

Financial Health

Current Ratio7.07
Quick Ratio7.07
Cash Ratio1.92
Debt / Equity0.00
Debt / Assets0.00%
Net Debt / EBITDA0.22
Interest Coverage-1080.17

Per-Share Data

Revenue per share0.00
Book Value per share3.23
Cash per share3.15
FCF per share-4.27
Tangible Book Value per share3.20
Dividend per share0.00

Related companies: ALLR · ASBP · CRIS · CTXR · ENTO · HOTH · LPTX

Explore sector: Healthcare · Biotechnology

More sections of BCTX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks